Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5840-5850

  Raynaud, Florence I ^a,f   Eccles, Suzanne ^a   Clarke, Paul A ^a   Hayes, Angela ^a   Nutley, Bernard ^a,g   Alix, Sonia ^a   Henley, Alan ^a   Di Stefano, Francesca ^a   Ahmad, Zahida ^a   Guillard, Sandrine ^a,f   Bjerke, Lynn M ^a,f   Kelland, Lloyd ^a,h   Valenti, Melanie ^a   Patterson, Lisa ^a   Gowan, Sharon ^a   Brandon, Alexis De Haven ^a   Hayakawa, Masahiko ^b   Kaizawa, Hiroyuki ^b   Koizumi, Tomonubu ^b   Ohishi, Takahide ^b   Patel, Sonal ^c   Saghir, Nahid ^c   Parker, Peter ^d   Waterfield, Mike ^e   Workman, Paul ^a,f   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ASTELLAS PHARMA INC   (Japan)

^c PIramed Ltd   (United Kingdom)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g 3650 Wesbrook Mall   (Canada)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA DEPENDENT PROTEIN KINASE; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PI 103; PROTEIN KINASE B; PROTEIN P110 ALPHA; PROTEIN P110 BETA; PROTEIN P110 DELTA; PROTEIN P110 GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASTROCYTOMA CELL; BIOLOGY; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MODEL; MODULATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; FURANS; HUMANS; IMMUNOBLOTTING; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250823572     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4615     Document Type: Article

References (58)

1. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;79:535-602.
2. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997;22:267-72.
3. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999;274:8347-50.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
5. Vanhaesebroeck, B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI 3-Kinase isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
6. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70S6k-dependent pathway. Cancer Res 1998;58:5239-47.
7. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
8. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
9. Rogers S, Box C, Harrington K, Rhys-Evans P, Eccles S. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in head and neck squamous cell carcinoma. Expert Opin Ther Targets 2005;9:769-90.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
11. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
12. Samuels Y, Diaz LA, Schmidt-Kittler O, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.
13. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas and medulloblastomas. Cancer Res 2004;64:5048-50.
14. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.
15. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, - gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006;103:1289-94.
16. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003;13:478-83.
17. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
18. Li Q, Zhu GD, Kokubo Y, et al. Targeting Serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treatingcancer. Curr Top Med Chem 2002;2:939-71.
19. Findlay GM, Harrington LS, Lamb RF. TSC1-2 tumour suppressor and regulation of mTOR signalling: linkingcell growth and proliferation. Curr Opin Genet Dev 2005;15:69-76.
20. Bell HS, Ryan KM. Intracellular signalling and cancer: complex pathways lead to multiple targets. Eur J Cancer 2005;41:206-15.
21. Jimenez C, Portela RA, Mellado M. Role of the PI 3-Kinase regulatory subunit in the control of actin organization and cell migration. J Cell Biol 2000;151:249-62.
22. Brader S, Eccles SA. Phosphoinositide 3′ kinase signalling pathways in tumour progression, invasion and angiogenesis. Tumori 2004;90:2-8.
23. Shien T, Doihara H, Hara H, et al. PLC and PI 3-Kinase pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). Breast Cancer 2004;11:367-73.
24. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M. Class II phosphoinositide 3-kinase defines a novel signalling pathway in cell migration. J Cell Biol 2005;169:789-99.
25. Workman P. Inhibitingt he phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004;32:393-6.
26. Drees BE, Mills GB, Rommel C, Prestwich GD. Therapeutic potential of phosphoinositide 3-kinase inhibitors. In: Expert Opin Ther 2004 Patents. Ashley Publications. 14:703-25.
27. Yu K, Lucas J, Zhu T, et al. PWT-458, A novel pegylated-17- hydroxywortmannin, Inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumours. Cancer Biol Ther 2005;4:538-45.
28. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumour activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72.
29. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol- 3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lungcancer xenografts. Mol Cancer Ther 2005;9:1349-57.
30. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumour activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56.
31. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg M ed Chem 2006;14:6847-58.
32. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett 2007;17:2438-42. Epub ahead of print 2007 Feb 15.
33. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of pyrido[3',2':4, 5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg M ed Chem Lett 2007;1:2438-42.
34. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-47.
35. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9.
36. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24:794-6.
37. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366-73.
38. Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P. Evaluation of the cassette dosingap proach for assessing the pharmacokinetics of geldanamycin analogues in mice. Cancer Chemother Pharmacol 2004;54:475-86.
39. Workman P, Balmain A, Hickman JA. United Kingdom Co-ordinating Committee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia. Second edition UKCCR. Br J Cancer 1997;77:1-10.
40. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis, concepts and applications, 1997 3rd ed. Stockholm (Sweden): Swedish Pharmaceutical Press; ISBN 91-8627-492-9.
41. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 1994;54:5171-7.
42. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-32.
43. Shingu T, Yamada K, Hara N, et al. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J Neurosurg 2003;98:154-61.
44. Lu Y, Lin YZ, LaPushin R, et al. The PTEN/MMAC1/TEP tumour suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999;18:7034-45.
45. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-64.
46. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylatingand inhibitinga Forkhead transcription factor. Cell 1999;96:857-68.
47. Nutley BP, Raynaud FI, Hayes A, Goddard P, Jarman M, Workman P. (2001). Pharmacokinetics and metabolism of the phosphatidylinositol-3 kinase inhibitor LY294002 in the mouse. Proc Am Assoc Cancer Res 2001;42:2044.
48. Nutley BP, Smith NF, Hayes A, et al. Pharmacokinetics and metabolism of a novel DNA-PK inhibitor NU7026. Br J Cancer 2005;93:1011-8.
49. 1 cyclins are regulated by PI 3-Kinase/AKT/mTOR/ p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287:C281-91.
50. Erhardt P, Cooper GM. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. J Biol Chem 1996;271:17601-4.
51. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
52. Poh TW, Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide3-kinase-Akt pathway. Cancer Res 2005;65:6264-74.
53. Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19.
54. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999;402:313-20.
55. Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras bindingto its effector phosphoinositide 3-kinase gamma. Cell 2000;103:931-43.
56. Jones GE, Prigmore E, Calvez R, et al. Requirement for PI 3-Kinase gamma in macrophage migration to MCP-1 and CSF-1. Exp Cell Res 2003;290:20-31.
57. Kaufmann J, Pronk G, Giese K, Klippel A. Identification of novel effectors of invasive growth downstream of phosphoinositide 3-kinase. Biochem Soc Trans 2004;32:355-9.
58. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.